search
Back to results

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Primary Purpose

Dry Eye Syndromes, Meige Syndrome, Blepharospasm

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Wumeiwan Jiawei Fang
botulinum toxin A
Sponsored by
China Academy of Chinese Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye Syndromes focused on measuring Wumeiwan Jiawei Fang, Blepharospasm, Meige syndrome

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Idiopathic blepharospasm met the diagnostic criteria. The age ranges from 18 to 80 years. Liver Yang deficiency,mixed syndrome of cold and heat. Signed Informed consent Exclusion Criteria: Secondary blepharospasm due to keratoconjunctivitis, trichiasis, and blepharitis. Open eyelid disuse. hemifacial spasm. The patient had undergone eye surgery in the previous 6 months. Allergic to the ingredients in the medicine. Corneal lenses were worn during the study. A woman who is pregnant or breastfeeding. Combined with cardiovascular, cerebrovascular,Liver and kidney function, hematopoietic system serious primary disease, mental patients, combined with stroke patients. At the same time, use drugs that interfere with the evaluation of drug efficacy. Idiopathic blepharospasm is treated with other drugs.

Sites / Locations

  • Eye Hospital, China Academy of Chinese Medical Sciences;GuangAnmen Hospital, China Academy of Chinese Medical Sciences;XiYuan Hospital, China Academy of Chinese Medical SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Wumeiwan Jiawei Fang

botulinum toxin A

Arm Description

This group will take Wumei pill granule orally.

In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.

Outcomes

Primary Outcome Measures

The degree of relief of blepharospasm was evaluated by Jankovic Rating Scale.
According to the Jankovic Rating Scale (JRS), in terms of severity and frequency, the score ranges from 0 to 4, with the highest score being 8. The higher the score is, the more severe the spasm is.
The Blepharospasm Disability Index (BSDI) was used to evaluate the impact of blepharospasm on daily living activities before and after treatment.
A total of 6 items were included, including walking, reading, driving, shopping, watching television and general activities. Each item was scored from 0 to 4 points and was self-evaluated by the patients. The total score of BSDI was 24 points.The higher the score is, the more severe the spasm is.
Traditional Chinese Medicine(TCM) syndrome scale evaluated the change of systemic syndrome before and after treatment.
The score for each syndrome is the sum of the highest scores obtained for each diagnosis of the syndrome. The full score is 30 points. Efficacy score = (Total score of pre-treatment symptoms➖Total post-treatment symptom score)/Total score of pre-treatment symptoms×100%. Symptoms basically disappear, reducing by 95 to 100 percent; Obvious effect: symptoms decreased significantly, reaching more than 75%; Effective: symptoms decreased to more than 55%; Ineffective: No or slightly reduced symptoms, only less than 50%..
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
According to whether there are common side effects of botulinum toxin such as ptosis, diplopia, photophobia, dry eye, gastrointestinal tract of exposed keratitis, whether there are gastrointestinal reactions and other side effects that may be related to the Chinese medicine granule preparation in this study.
According to the Jankovic rating scale, the recurrence was determined at 14 days, 42 days, 3 months and 6 months after medication
According to the Jankovic rating scale, the recurrence situation at 14 days, 42 days, 3 months and 6 months after medication was determined, and the increase of spasm intensity by 1 grade or more was considered as recurrence.
Number of participants with treatment-related adverse events as assessed by systemic response, routine blood tests, liver function (ALT), kidney function (BUN, Cr).
Systemic reaction (record at any time); Routine blood tests: the detection points were 14 days, 42 days, 3 months and 6 months after the first visit and treatment; Liver function (ALT), kidney function (BUN, Cr) : The detection points were 14 days, 42 days, three months and six months after the first visit and treatment.

Secondary Outcome Measures

Full Information

First Posted
October 21, 2022
Last Updated
November 15, 2022
Sponsor
China Academy of Chinese Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05618470
Brief Title
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Official Title
Randomized Controlled Clinical Study on Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 12, 2018 (Actual)
Primary Completion Date
August 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
China Academy of Chinese Medical Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.
Detailed Description
Idiopathic blepharospasm is an idiopathic dysfunction characterized by involuntary spasms of the eyelids bilaterally that interfere with visual function and cause ocular discomfort. The incidence has increased each year in recent years, and the disease may present with persistent eye closure or even functional blindness in advanced stages. In some patients, the disease may be associated with submandibular dystonia, known as Meige's syndrome. Currently, the disease is treated symptomatically. Such as oral.These treatments not only have large side effects, but also make it difficult to relieve the patient of multiple lesions in the eyes, face and tongue. Chinese medicine has unique advantages in treating this disease, highlighting the overall diagnosis and solving different parts of the disease in an integrated manner. Wu Mei Wan is a traditional Chinese medicine prescription, and our team has been using Wu Mei Wan Jia Wei Fang for the treatment of Meige syndrome since 2009 under the leadership of Gao Jiansheng, a famous Chinese medicine teacher in the capital, and found significant therapeutic effects in preliminary clinical observation, but there is a lack of large sample of randomized controlled clinical studies. In this study, we propose to systematically observe the efficacy of traditional Chinese medicine in the treatment of idiopathic blepharospasm by using the traditional sutra formula for idiopathic blepharospasm as a test group and local botulinum toxin A injection as a control group, and to scientifically evaluate the efficacy of the Wu Mei Wan Jia Wei Fang in the treatment of idiopathic blepharospasm.The results were evaluated in order to provide new treatment options for the clinical management of idiopathic blepharospasm (including Meige syndrome) and to benefit more patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndromes, Meige Syndrome, Blepharospasm, Hyperactivity
Keywords
Wumeiwan Jiawei Fang, Blepharospasm, Meige syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Wumeiwan Jiawei Fang
Arm Type
Experimental
Arm Description
This group will take Wumei pill granule orally.
Arm Title
botulinum toxin A
Arm Type
Active Comparator
Arm Description
In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.
Intervention Type
Drug
Intervention Name(s)
Wumeiwan Jiawei Fang
Other Intervention Name(s)
nothing
Intervention Description
orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
Intervention Type
Drug
Intervention Name(s)
botulinum toxin A
Other Intervention Name(s)
nothing
Intervention Description
Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
Primary Outcome Measure Information:
Title
The degree of relief of blepharospasm was evaluated by Jankovic Rating Scale.
Description
According to the Jankovic Rating Scale (JRS), in terms of severity and frequency, the score ranges from 0 to 4, with the highest score being 8. The higher the score is, the more severe the spasm is.
Time Frame
Six months
Title
The Blepharospasm Disability Index (BSDI) was used to evaluate the impact of blepharospasm on daily living activities before and after treatment.
Description
A total of 6 items were included, including walking, reading, driving, shopping, watching television and general activities. Each item was scored from 0 to 4 points and was self-evaluated by the patients. The total score of BSDI was 24 points.The higher the score is, the more severe the spasm is.
Time Frame
Six months
Title
Traditional Chinese Medicine(TCM) syndrome scale evaluated the change of systemic syndrome before and after treatment.
Description
The score for each syndrome is the sum of the highest scores obtained for each diagnosis of the syndrome. The full score is 30 points. Efficacy score = (Total score of pre-treatment symptoms➖Total post-treatment symptom score)/Total score of pre-treatment symptoms×100%. Symptoms basically disappear, reducing by 95 to 100 percent; Obvious effect: symptoms decreased significantly, reaching more than 75%; Effective: symptoms decreased to more than 55%; Ineffective: No or slightly reduced symptoms, only less than 50%..
Time Frame
Six months
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description
According to whether there are common side effects of botulinum toxin such as ptosis, diplopia, photophobia, dry eye, gastrointestinal tract of exposed keratitis, whether there are gastrointestinal reactions and other side effects that may be related to the Chinese medicine granule preparation in this study.
Time Frame
Six months
Title
According to the Jankovic rating scale, the recurrence was determined at 14 days, 42 days, 3 months and 6 months after medication
Description
According to the Jankovic rating scale, the recurrence situation at 14 days, 42 days, 3 months and 6 months after medication was determined, and the increase of spasm intensity by 1 grade or more was considered as recurrence.
Time Frame
Six months
Title
Number of participants with treatment-related adverse events as assessed by systemic response, routine blood tests, liver function (ALT), kidney function (BUN, Cr).
Description
Systemic reaction (record at any time); Routine blood tests: the detection points were 14 days, 42 days, 3 months and 6 months after the first visit and treatment; Liver function (ALT), kidney function (BUN, Cr) : The detection points were 14 days, 42 days, three months and six months after the first visit and treatment.
Time Frame
Six months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Idiopathic blepharospasm met the diagnostic criteria. The age ranges from 18 to 80 years. Liver Yang deficiency,mixed syndrome of cold and heat. Signed Informed consent Exclusion Criteria: Secondary blepharospasm due to keratoconjunctivitis, trichiasis, and blepharitis. Open eyelid disuse. hemifacial spasm. The patient had undergone eye surgery in the previous 6 months. Allergic to the ingredients in the medicine. Corneal lenses were worn during the study. A woman who is pregnant or breastfeeding. Combined with cardiovascular, cerebrovascular,Liver and kidney function, hematopoietic system serious primary disease, mental patients, combined with stroke patients. At the same time, use drugs that interfere with the evaluation of drug efficacy. Idiopathic blepharospasm is treated with other drugs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
wei yang
Phone
18600484803
Ext
010-68686185
Email
506910548@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
wei yang
Organizational Affiliation
China Academy of Chinese Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eye Hospital, China Academy of Chinese Medical Sciences;GuangAnmen Hospital, China Academy of Chinese Medical Sciences;XiYuan Hospital, China Academy of Chinese Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
10040
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xi Chen
Phone
15300307564

12. IPD Sharing Statement

Learn more about this trial

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

We'll reach out to this number within 24 hrs